Skip to main content
Clinical Trials/ACTRN12616000592448
ACTRN12616000592448
Completed
未知

Developmental and sequenced one to one educational intervention (DS1-EI) for autism spectrum disorder: a randomized single-blind controlled trial.

Croix Rouge Francaise0 sites70 target enrollmentMay 6, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Autism Spectrum Disorder
Sponsor
Croix Rouge Francaise
Enrollment
70
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 6, 2016
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Croix Rouge Francaise

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria :
  • \- a current diagnosis of ASD confirmed by clinical assessment and the Autism Diagnostic Interview\-Revised;
  • \- a developmental quotient less than or equal to 24 months;
  • \- no fluent oral language
  • \- aged between 5 to 9 years.
  • \- Controls are matched for sex, age, IQ, study sites before randomization

Exclusion Criteria

  • Exclusion criteria :
  • \- parents’ refusal to participate;
  • \- family project to change institution in the short term whatever the reason;
  • \- patient’s agitation, hyperactivity or behavioral problems that would challenge presence in classroom.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
SOBERANA 02Prevention of COVID-19COVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus
RPCEC00000340Finlay Vaccine Institute (IFV)40
Completed
Phase 1
SOBERANA PEDIATRIACOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus
RPCEC00000374Finlay Vaccine Institute (IFV)350
Completed
Phase 1
A Phase 1, Adaptive, Single and Multiple Ascending Dose Study of EMA401 Sodium Salt Administered Orally in Healthy, Adult Males to Determine the Maximum Tolerated Dose and Pharmacokinetic Profiles
ACTRN12614000802606Spinifex Pharmaceuticals Pty Ltd84
Active, not recruiting
Phase 1
Sealing pancreato-enteric anastomosis with TachoSilpancreatic surgery - evaluation of the effect of fibrin-coated collagenMedDRA version: 18.0Level: PTClassification code 10049192Term: Pancreatic fistulaSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 18.0Level: LLTClassification code 10050457Term: Pancreatic anastomotic leakSystem Organ Class: 100000004863Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
EUCTR2013-000639-29-ATABCSG (Austrian Breast & Colorectal Cancer Study Group)
Active, not recruiting
Phase 1
A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)MedDRA version: 9.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stage
EUCTR2008-001679-31-CZGemin X Pharmaceuticals US, Inc.